To boost Oncology portfolio Pfizer agreed to acquire Trillium Therapeutics for approximately $2.26 billion. Trillium is a leading clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
- Trilliums portfolio includes biologics that are designed to enhance the ability of patients innate immune system to detect and destroy cancer cells.
- TTI-622 and TTI-621 are novel, potentially best-in-class SIRP?-Fc fusion proteins that are currently in Phase 1b/2 development across several indications, with a focus on hematological malignancies.
- Hematological malignancies are cancers that affect the blood, bone marrow, and lymph nodes.
The prominent expansions and deals by Pfizer ate mentioned below:
April 2021: In order to accelerate development of therapies, Pfizer Inc. had acquired Amplyx Pharmaceuticals, Inc. The San Diego, California, based Amplyx Pharmaceuticals, Inc., is a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases.
March 2021: To boost biologics manufacturing in China, WuXi Biologics announced to acquire DS and DP manufacturing facilities from Pfizer. The deal helps will boost the commercial Drug Substance (DS) and Drug Product (DP) capacities for WuXi Biologics to address surging manufacturing demands.
Nov 2020: The global pharmaceutical company, Pfizer Inc. in association with BioNTech SE announced the execution of an agreement with the U.S.
Department of Health and Human Services and the Department of Defense to provide 300 million doses of a vaccine for COVID-19 in 2021
July 2020: Pfizer Inc. and BioNTech SE announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses.
July 2020: Pfizer Inc. had pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, to help address the significant global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections.
Dec 2019: Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. and Pfizer Inc. announced that the companies had been entered into a global license agreement for Theravance Biopharmas preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized.
Pfizer, headquartered in New York, United States, is a global pharmaceutical corporation. The company involves in discovery, development and manufacturing of health care products globally. Its global portfolio includes medicines and vaccines as well as many of the world’s best?known consumer health care products.